US FDA grants new fast-track voucher to Partner Therapeutics' bile duct cancer drug
- Posted on May 6, 2026
- By Bing News
- 0 Views
- 1 min read
US FDA grants new fast-track voucher to Partner Therapeutics' bile duct cancer drug
May 6 (Reuters) - Private biotech firm Partner Therapeutics said on Wednesday the U.S. Food and Drug Administration has granted a priority review voucher to its experimental bile duct cancer drug as part of a new fast-track review program. • The antibody drug, Bizengri, is under review for adults with advanced cholangiocarcinoma whose tumors carry a rare genetic mutation and whose disease has
